Thermo Fisher Scientific CD19 Monoclonal Antibody (LC1), eBioscience

Applications

Tested Dilution

Publications

Western Blot (WB)

2-5 µg/mL

-

Immunohistochemistry (Paraffin) (IHC (P))

1-10 µg/mL

-

Product Specifications

Species Reactivity

Human, Mouse

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

LC1

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_11219274

Product Specific Information

Description: The LC1 monoclonal antibody reacts with human CD19, a 95 kDa transmembrane glycoprotein. CD19 is expressed by B cells during all stages of development excluding the terminally differentiated plasma cells. Follicular dendritic cells also express CD19. Together CD21, CD81, Leu13, MHC class II, and CD19 form a multi-molecular complex that associates with BCR. Signaling through CD19 induces tyrosine phosphorylation, calcium flux and proliferation of B cells. The antibody recognizes a sequence near the carboxy terminus.

Applications Reported: This LC1 antibody has been reported for use in western blotting and immunohistochemical staining of formalin-fixed paraffin embedded tissue sections.

Applications Tested: This LC1 antibody has been tested by western blot and can be used at less than or equal to 5 µg/mL. This antibody has also been tested by immunohistochemistry on FFPE human tonsil using high pH antigen retrieval at less than or equal to 10 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains. CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias. Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.